Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
Tony Mok, Solange Peters, D. Ross Camidge, Johannes Noé, Shirish M. Gadgeel, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Krzysztof Konopa, Emanuela Pozzi, Ting Liu, Isabell R. Loftin, Crystal Williams, Alice T. Shaw
Topics & Concepts
MedicineFluorescence in situ hybridizationImmunohistochemistryIn situ hybridizationIn situPathologyInternal medicineOncologyGeneGeneticsBiologyGene expressionMeteorologyChromosomePhysicsLung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment